Overcoming immune checkpoint inhibitor-mediated T-cell exhaustion with a TCR beta chain-directed selective dual T-cell activator
Authors: Angstadt, Shantel; Horn, Lucas A; Fousek, Kristen; Rajabian, Nika; Qin, Haiyan; Medina-Enriquez, Miriam M; Kelly, Marcus D; Hsiao-Sanchez, Nicole; Meyer, Thomas J; Moisan, Jacques; Katragadda, Madan; Bayliffe, Andrew; Su, Zhen; Schlom, Jeffrey; Palena, Claudia
Source journal: Journal of experimental & clinical cancer research : CR (2026-08-28)
DOI: 10.1186/s13046-026-03815-2
Abstract
BACKGROUND: Resistance to immune checkpoint inhibition (ICI) using antibodies against the PD-1/PD-L1 axis remains a significant clinical challenge. Here, we report that combination of anti-PD-1 with a bifunctional fusion molecule, anti-TCRbeta-IL-2, comprised of a monovalent Fab that binds and activates the T-cell receptor (TCR) through distinct variable beta (Vbeta) chain residues and an IL-2 molecule, mediates robust anti-tumor control in the context of ICI resistance. METHODS: Syngeneic murine models with varying levels of ICI-resistance were used to assess sensitization to ICI in combination with the anti-TCRbeta-IL-2 therapy. Mechanisms of the combination therapy's benefit were investigated by profiling tumor-infiltrating lymphocytes via flow cytometric, single cell transcriptomic, and histological analyses. Immune response efficacy and diversification was identified by the generation of multifunctional, tumor-associated antigen-specific and neoantigen-specific T-cell responses post-therapy. RESULTS: Unlike anti-PD-1 therapy alone that resulted in expansion of terminally exhausted CD8(+) T cells and lack of anti-tumor effect, administration of anti-TCRbeta-IL-2 followed by anti-PD-1 greatly enhanced anti-tumor efficacy leading to tumor cures and long-term protection in several murine models resistant to ICI. Analysis of tumor-infiltrating lymphocytes showed increased proliferation and markers of cytotoxicity in CD8(+) and CD4(+) T cells, reduced CD8(+) T-cell exhaustion, and decreased proportion of regulatory CD4(+) T cells in tumors of mice receiving TCRbeta-IL-2 followed by anti-PD-1. Diversification of the immune response with increased number of multifunctional, neoantigen-specific T cells was observed in mice receiving anti-TCRbeta-IL-2 followed by anti-PD-1, compared to each of the monotherapies. CONCLUSIONS: A novel T-cell activation mechanism sensitizes refractory tumors to ICI via T-cell function revival and epitope spreading. From these results, a clinical trial is planned to evaluate the combination of an anti-TCRbeta-IL-2 agent (invikafusp alfa) and anti-PD-1 in ICI-refractory non-small cell lung and castration-resistant metastatic prostate cancers.
Related topics
Related open access articles
- Emerging mycotoxins in botanicals: benefit and risk
- A Brief Review on Core/shell Quantum Dots
- In vitro cytotoxicity studies on galactosylated chitosan nanoparticles for the delivery of oridonin to liver
- Separation of Six Lupane-Type Triterpenoid Saponins from Leaves of Acanthopanax gracilistylus by HSCCC with Preparative-HPLC
- Chemical characterization of polyphenol extracts from Andean and industrial Solanum tuberosum tubers and their cytotoxic activity on human hepatocarcinoma cells
- Effects of Stresses on the Growth and Cytotoxicity of Shiga-Toxin Producing Escherichia coli in Ground Beef and Spinach
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.